p47 gene therapy

Drug Profile

p47 gene therapy

Alternative Names: Chronic granulomatous disease gene therapy

Latest Information Update: 16 Jul 2002

Price : $50

At a glance

  • Originator Baxter International; Cell Genesys
  • Class Gene therapies
  • Mechanism of Action Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic granulomatous disease

Most Recent Events

  • 16 Jul 2002 Discontinued - Phase-I for Chronic granulomatous disease in USA (Infusion)
  • 12 Dec 2001 No-Development-Reported for Chronic granulomatous disease in USA (Infusion)
  • 08 Apr 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top